New metabolomics solution enables understanding of the microbiome 

Metabolon’s first offering from its SmartPanel portfolio aims to provide drug discovery and precision medicine researchers with a novel, dynamic process to explore biologically relevant views of metabolomic data in the context of specific metabolic pathways, biological themes, and disease associations. 

“The metabolome offers a window into human biology, providing insights on the human body’s response to chemicals and revealing the biological fingerprint to enable data-driven decisions. This ‘omics technology also reveals the potential utility of drugs for specific indications,” said Rangaprasad (Ranga) Sarangarajan, Chief Scientific Officer of Metabolon. “The metabolome represents the end-point product of complex network biology. Metabolomics is an untapped, underappreciated biological resource. It can significantly contribute to the evolution of healthcare system technologies because the insights revealed influence almost every aspect of health, treatment of diseases, and health outcomes.” 

“Metabolomics is a potent and incredibly powerful tool for drug developers because it provides real-time, functional insight of the phenotype,” said Rohan Hastie, President and CEO of Metabolon. “But we’ve also heard from our commercial clients that the sheer volume of data we provide from our industry-leading untargeted platform can be overwhelming. Our SmartPanel solution offers a focused view of biologically relevant metabolites in a dynamic format that allows researchers to explore comparisons and associations of data most relevant to their unique study.”  

The Microbiome SmartPanel can be used to discover microbiota-related biomarkers and for elucidating the mechanism of action of therapeutics and it may also inform on dose selection and efficacy. The company has plans to unveil additional SmartPanel offerings in the coming months and is developing novel methods for a number of new Targeted Assays, which can be validated up to Good Clinical Practice (GCP) requirements if needed. 

Hastie concluded: “Our belief is that by making metabolomics solutions more accessible for use by the broader market, we can make it possible for more drug developers to leverage the power of metabolomics to develop new therapies to improve patient care.” 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free